Auxly Cannabis Group Inc.
TSX:XLY.TODrug Manufacturers - Specialty & Generic
+$0.00 today
- Market cap
- $364.42M
- Beta
- 1.16
- P/E (TTM)
- 7.3
- EPS (TTM)
- $0.02
Volume 0.13M
Average 0.71M
XLY.TO Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Auxly Cannabis Group Inc.TSX: XLY.TO
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development remains negative
Q1 FY2026 research & development was CA$0, compared with CA$33K a year earlier. Trailing-twelve-month research & development was CA$267K.
Context
- Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near CA$0 or moves back toward the trailing-twelve-month quarterly average of CA$66.75K.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
CAD · from the income statement
- Latest · FY2025
- 0 CAD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | -100.0% |
| FY2023 | 2023-12-31 | 497K | +70.2% |
| FY2022 | 2022-12-31 | 292K | -2.0% |
| FY2021 | 2021-12-31 | 298K | — |
Research & Development vs competitors
How XLY.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +62.8% is the highest of 2, against a peer median of +5.3%.
- Research & development amounts to 0.2% of revenue for XLY.TO, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$15.21M CAD | +5.3% | -9.6% | — | |
| LTM Mar 2026 | CA$267K CAD | +62.8% | — | 0.2% | |
| LTM Mar 2026 | CA$0 CAD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding XLY.TO) | — | +5.3% | -9.6% | 0.0% | |
Competitors are the stored peer set for XLY.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 83.83M | 94.47M | 101.08M | 122.33M | 151.48M |
| Cost of Revenue | 64.54M | 77.96M | 79.8M | 62.4M | 64.74M |
| Gross Profit | 19.29M | 16.51M | 21.28M | 59.93M | 86.74M |
| Gross Margin | 23.0% | 17.5% | 21.1% | 49.0% | 57.3% |
| Research & Development | 298K | 292K | 497K | 0 | 0 |
| Selling, General & Admin | 45.42M | 50.38M | 40.28M | 40.73M | 49.07M |
| Operating Expenses | 58.23M | 65.49M | 47.23M | 45.22M | 54.07M |
| Depreciation & Amortization | 14.27M | 20.18M | 11.21M | 10.28M | 11.45M |
| EBITDA | (18.3M) | (94.79M) | (10.89M) | 24.38M | 50.31M |
| EBITDA Margin | -21.8% | -100.3% | -10.8% | 19.9% | 33.2% |
| Operating Income | (38.94M) | (48.98M) | (25.95M) | 14.71M | 32.67M |
| Operating Margin | -46.4% | -51.8% | -25.7% | 12.0% | 21.6% |
| Interest Income | 1.59M | 337K | 32K | 240K | 130K |
| Interest Expense | 17.67M | 21.58M | 25.65M | 14.46M | 6.34M |
| Other Income / Expenses | (11.3M) | (87.58M) | (21.8M) | (15.07M) | (155K) |
| Income Before Tax | (50.24M) | (136.56M) | (47.75M) | (356K) | 32.52M |
| Pre-Tax Margin | -59.9% | -144.5% | -47.2% | -0.3% | 21.5% |
| Income Tax Expense | (4.33M) | (6.26M) | (3.24M) | 15.99M | (9.34M) |
| Net Income | (33.74M) | (130.29M) | (44.51M) | (16.35M) | 41.86M |
| Net Margin | -40.2% | -137.9% | -44.0% | -13.4% | 27.6% |
| EPS (Basic) | (0.06) | (0.15) | (0.04) | (0.01) | 0.03 |
| EPS (Diluted) | (0.06) | (0.15) | (0.04) | (0.01) | 0.03 |
| Weighted Avg Shares | 783.38M | 889.87M | 990.99M | 1.2B | 1.33B |
| Weighted Avg Shares (Diluted) | 783.38M | 889.87M | 990.99M | 1.2B | 1.59B |
Auxly Cannabis Group Inc.
TSX:XLY.TO
Intrinsic Alpha fair value
Locked
Current Price
$3.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.